title: Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase.
abstract: OBJECTIVE
  To investigate whether intrapericardial urokinase irrigation along with pericardiocentesis could prevent pericardial constriction in patients with infectious exudative pericarditis.
  
  
  METHODS
  A total of 94 patients diagnosed as infectious exudative pericarditis (34 patients with purulent pericarditis and 60 with tuberculous pericarditis, the disease courses of all patients were less than 1 month), 44 males and 50 females, aged from 9 to 66 years (mean 45.4 +/- 14.7 years), were consecutively recruited from 1993 to 2002. All individuals were randomly given either intrapericardial urokinase along with conventional treatment in study group, or conventional treatment alone (including pericardiocentesis and drainage) in control group. The dosage of urokinase ranged from 200000 to 600000 U (mean 320000 +/- 70000 U). The immediate effects were detected by pericardiography with sterilized air and diatrizoate meglumine as contrast media. The long-term investigation depended on the telephonic survey and echocardiographic examination. The duration of following-up ranged from 8 to 120 months (mean 56.8 +/- 29.0 months).
  
  
  RESULTS
  Percutaneous intrapericardial urokinase irrigation promoted complete drainage of pericardial effusion, significantly reduced the thickness of pericardium (from 3.1 +/- 1.6 mm to 1.6 +/- 1.0 mm in study group, P < 0.001; from 3.4 +/- 1.6 mm to 3.2 +/- 1.8 mm in control group, P > 0.05, respectively), and alleviated the adhesion. Intrapericardial bleeding related to fibrinolysis was found in 6 of 47 patients with non-blood pericardial effusion and no systemic bleeding and severe puncture-related complication was observed. In follow-up, there was no cardiac death, and pericardial constriction events were observed in 9 (19.1%) of study group and 27 (57.4%) of control group. Cox analysis illustrated that urokinase could significantly reduce the occurrence of pericardial constriction (relative hazard coefficient = 0.185, P < 0.0001).
  
  
  CONCLUSIONS
  The early employment of intrapericardial fibrinolysis with urokinase and pericardiocentesis appears to be safe and effective in preventing the development of pericardial constriction in patients with infectious exudative pericarditis.
authors.affiliation: Department of Cardiology, First Hospital, Xi'an Jiaotong University, Xi'an 710061. hanbincui@hotmail.com
authors.forename: Han-bin
authors.initials: HB
authors.lastname: Cui
authors.forename: Xin-yi
authors.initials: XY
authors.lastname: Chen
authors.forename: Chang-cong
authors.initials: CC
authors.lastname: Cui
authors.forename: Xi-ling
authors.initials: XL
authors.lastname: Shou
authors.forename: Xin-hong
authors.initials: XH
authors.lastname: Liu
authors.forename: Xiao-wei
authors.initials: XW
authors.lastname: Yao
authors.forename: Jun-kui
authors.initials: JK
authors.lastname: Wang
authors.forename: Gong-chang
authors.initials: GC
authors.lastname: Guan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020519:Pericardiocentesis; D010493:Pericarditis / Q000188:drug therapy* / Q000628:therapy; D010494:Pericarditis, Constrictive / Q000517:prevention & control*; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator